Lb Pharmaceuticals Inc (LBRX): Hedge Fund Ownership & Smart Money Signals (Q1 2026)

Q: Is it too late to buy Lb Pharmaceuticals Inc (LBRX) following the 2026 Q1 hedge fund 13F filings?

As of today, LBRX has moved -4.2% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of -10.2%. Since the quarter end (March 31, 2026), LBRX gained +15.2% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Lb Pharmaceuticals Inc (LBRX)

75 + Investors. Track Smart Money conviction in LBRX. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — LBRX

Based on 75 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added LBRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

75 hedge funds hold LBRX right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +7400% more funds vs a year ago

fund count last 6Q

+74 new funds entered over the past year (+7400% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 67% buying

50 buying25 selling

Last quarter: 50 funds were net buyers (20 opened a brand new position + 30 added to an existing one). Only 25 were sellers (13 trimmed + 12 sold completely). A clear majority buying is a strong confirmation signal.

⚠️

Fewer new buyers each quarter (-12 vs last Q)

new funds entering per quarter

Funds opening this position for the first time: 0 → 52 → 32 → 20. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.

🔄

Mostly new holders — 95% entered in last year

■ 4% conviction (2yr+) ■ 1% medium ■ 95% new

Only 3 funds (4%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

➡️

Steady discovery — ~20 new funds/quarter

0 → 0 → 52 → 32 → 20 new funds/Q

New funds entering each quarter: 0 → 52 → 32 → 20. Consistent flow of new institutional buyers without clear acceleration or slowdown.

🌱

Early stage — 95% of holders entered in last year

■ 5% veterans ■ 0% 1-2yr ■ 95% new

Of 75 current holders: 71 (95%) entered in the past year, only 4 (5%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.

📋

Smaller funds dominant — 13% AUM from top-100

13% from top-100 AUM funds

25 of 75 holders rank in the top 100 by AUM, but together hold only 13% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

7.4

out of 10

High Exit Risk

Exit risk score 7.4/10 — multiple crowding signals converge. Institutional ownership is at 100% of its all-time high — near peak crowding. Crowded trades can unwind fast — a single catalyst can trigger a cascade.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q1)	Prior (2025 Q4)	Change
Funds Holding	75	67	11.94%
13F Shares	27M	25M	8.0%
Total Value	$659M	$552M	19.42%
New Positions	20	32	-12
Increased Positions	30	13	+17
Closed Positions	12	18	-6
Reduced Positions	13	12	+1
Total Calls	0	0	-
Total Puts	0	0	-
PUT/CALL Ratio	0.0	0.0	Bullish

Metric

All 13F Filers (2026 Q1)

Prior (2025 Q4)

Change

Funds Holding

11.94%

13F Shares

27M

25M

8.0%

Total Value

$659M

$552M

19.42%

New Positions

-12

Increased Positions

+17

Closed Positions

-6

Reduced Positions

Total Calls

Total Puts

PUT/CALL Ratio

0.0

Bullish

Institutional Holders (2026 Q1)

75 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in LBRX. Verified SEC 13F-HR filings.

QUARTER:

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 LBRX holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Nan Fung Group Holdings Ltd	12.82%	630,657	$15.6M
2	Spruce Street Capital LP	8.09%	1,376,159	$33.6M
3	Trails Edge Capital Partners, LP	7.45%	1,319,362	$32.5M
4	Caligan Partners LP	2.30%	1,438,070	$34.6M
5	Commodore Capital LP	2.14%	1,500,000	$37.0M
6	Great Point Partners LLC	1.70%	300,000	$7.4M
7	Vivo Capital, LLC	1.65%	800,000	$19.7M
8	Deep Track Capital, LP	1.35%	3,352,804	$82.7M
9	TCG Crossover Management, LLC	1.30%	1,839,489	$45.3M
10	HighVista Strategies LLC	1.18%	173,595	$4.3M
11	Logos Global Management LP	1.13%	915,000	$22.6M
12	Nantahala Capital Management, LLC	0.96%	1,052,894	$26.0M
13	Ra Capital Management, L.P.	0.58%	2,208,604	$54.5M
14	Acuta Capital Partners, LLC	0.50%	28,919	$713K
15	Stempoint Capital LP	0.24%	50,000	$1.2M
16	Boxer Capital Management, LLC	0.23%	70,000	$1.7M
17	Integral Health Asset Management, LLC	0.18%	150,000	$3.7M
18	Eversept Partners, LP	0.13%	100,198	$2.5M
19	Alyeska Investment Group, L.P.	0.06%	863,947	$21.3M
20	Opaleye Management Inc.	0.05%	14,506	$358K
21	Balyasny Asset Management L.P.	0.03%	923,694	$22.8M
22	Baker BROS. Advisors LP	0.03%	200,000	$4.9M
23	Meyer Handelman Co	0.01%	15,094	$372K
24	Soleus Capital Management, L.P.	0.01%	10,000	$247K
25	Jennison Associates LLC	0.01%	538,216	$13.3M

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Lb Pharmaceuticals Inc (LBRX)

What does the Smart Money Trend signal show for LBRX?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added LBRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for LBRX?

More buyers than sellers — 67% buying: Last quarter: 50 funds were net buyers (20 opened a brand new position + 30 added to an existing one). Only 25 were sellers (13 trimmed + 12 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for LBRX holders?

Smaller funds dominant — 13% AUM from top-100: 25 of 75 holders rank in the top 100 by AUM, but together hold only 13% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held LBRX?

Mostly new holders — 95% entered in last year: Only 3 funds (4%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Lb Pharmaceuticals Inc (LBRX) following the 2026 Q1 hedge fund 13F filings?

As of today, LBRX has moved -4.2% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of -10.2%. Since the quarter end (March 31, 2026), LBRX has gained +15.2% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Lb Pharmaceuticals Inc (LBRX)

Smart Money Signals — LBRX

Buying streak — 3 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +7400% more funds vs a year ago

More buyers than sellers — 67% buying

Fewer new buyers each quarter (-12 vs last Q)

Mostly new holders — 95% entered in last year

Steady discovery — ~20 new funds/quarter

Early stage — 95% of holders entered in last year

Smaller funds dominant — 13% AUM from top-100

Institutional Sentiment Summary — LBRX

Hedge Fund Ownership: LBRX

Market Analysis: LBRX

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: LBRX

Is It Too Late to Buy Lb Pharmaceuticals Inc (LBRX) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: LBRX

Statistics: LBRX

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q1)

Frequently Asked Questions — Lb Pharmaceuticals Inc (LBRX)

Welcome to 13Foresight!